<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04466410</url>
  </required_header>
  <id_info>
    <org_study_id>XT-150-1-0102</org_study_id>
    <nct_id>NCT04466410</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of XT-150 for Treatment of Neuropathic Pain</brief_title>
  <official_title>A Double Blind, Placebo Controlled, Preliminary Evaluation of Safety, Tolerability, and Efficacy of XT-150 for the Treatment of Neuropathic Pain</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Xalud Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Xalud Therapeutics, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Preliminary Evaluation of Safety, Tolerability, and Efficacy of XT-150 for the Treatment of&#xD;
      Neuropathic Pain. Intrathecally administered, single injection.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      XT-150 has been safe and well tolerated in clinical studies of intra-articular knee&#xD;
      injections for osteoarthritis.&#xD;
&#xD;
      This is the initial study of XT-150 for treatment of neuropathic pain. For this indication&#xD;
      XT-150 must be administered by intrathecal injection. Doses used in the osteoarthritis&#xD;
      studies will be studied for neuropathic pain.&#xD;
&#xD;
      Upon safety reviews, doses will be increased by cohorts.&#xD;
&#xD;
      The study is placebo controlled and blinded.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 14, 2021</start_date>
  <completion_date type="Anticipated">April 2023</completion_date>
  <primary_completion_date type="Anticipated">January 2023</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>Dose escalation by cohort following safety reviews</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Placebo and active drug are identical in appearance. Randomization will be provided to an unblinded pharmacist. Dosing and clinical assessments will be blinded.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Treatment-Emergent Adverse Events</measure>
    <time_frame>6 months</time_frame>
    <description>Adverse events</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Visual Analog Scale of Pain Intensity</measure>
    <time_frame>6 months</time_frame>
    <description>Change from Baseline score, 0 to 100 worst pain</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>West Haven-Yale Multidimensional Pain Inventory (WHYMPI/MPI)</measure>
    <time_frame>6 months</time_frame>
    <description>measures the impact of pain on patients' lives</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Multidimensional Pain Scale (MPS)</measure>
    <time_frame>6 months</time_frame>
    <description>Changes from baseline in pain</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neuropathic Pain Symptom Inventory (NPSI)</measure>
    <time_frame>6 months</time_frame>
    <description>Evaluates the relative component of neuropathic and nociceptive pain symptoms</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">48</enrollment>
  <condition>Neuropathic Pain</condition>
  <arm_group>
    <arm_group_label>Low Dose XT-150</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Lowest dose of XT-150. Cohort 1 of the study</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Middle dose XT-150</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Middle dose of XT-150. Cohort 2 of the study</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High Dose XT-150</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Highest dose of XT-150. Cohort 3 of the study</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>PBS for injection. 4 of 16 subjects randomly assigned in each experimental drug cohort</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>XT-150</intervention_name>
    <description>Single bolus intrathecal injection</description>
    <arm_group_label>High Dose XT-150</arm_group_label>
    <arm_group_label>Low Dose XT-150</arm_group_label>
    <arm_group_label>Middle dose XT-150</arm_group_label>
    <other_name>IL-10 transgene plasmid DNA injected intrathecally</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Signed Informed Consent Form&#xD;
&#xD;
          2. Male or female, between 18 and 80 years of age, inclusive&#xD;
&#xD;
          3. Clinical indication: Lumbar disk disease with no prior lumbar surgery with radicular&#xD;
             pain symptoms and/or signs of compressive neuropathy&#xD;
&#xD;
          4. Inadequate pain relief (visual analog scale of pain intensity [VASPI] score ≥60 mm on&#xD;
             a 0-100 mm scale) lasting ≥3 months&#xD;
&#xD;
          5. Medically stable as determined by the Principal Investigator in consultation with the&#xD;
             Sponsor's Medical Monitor, based on pre-study medical history, physical examination,&#xD;
             and clinical laboratory tests&#xD;
&#xD;
          6. In the judgment of the Principal Investigator, acceptable vital signs: blood pressure;&#xD;
             resting heart rate; respirations, and oral temperature&#xD;
&#xD;
          7. Life expectancy &gt;6 months as determined by the Principal Investigator&#xD;
&#xD;
          8. Female subjects of child-bearing potential, and those &lt;1 year post-menopausal, must be&#xD;
             practicing highly effective methods of birth control such as hormonal methods (e.g.,&#xD;
             combined oral, implantable, injectable, or transdermal contraceptives), double barrier&#xD;
             methods (e.g., condoms, sponge, diaphragm, or vaginal ring plus spermicidal jellies or&#xD;
             cream), or total abstinence from heterosexual intercourse for a minimum of 1 full&#xD;
             menstruation cycle before study drug administration and agree to continue abstinence&#xD;
             for 1 full menstruation cycle after the study is completed&#xD;
&#xD;
          9. Male subjects who are heterosexually active, and not surgically sterile, must agree to&#xD;
             use effective contraception for the duration of the study and for 1 month after the&#xD;
             study is completed&#xD;
&#xD;
         10. Stable medical regimen for ≥2 months before participation&#xD;
&#xD;
         11. Have suitable lumbar anatomy for intrathecal injection as determined by MRI or X-Ray&#xD;
             in the last 6 months.&#xD;
&#xD;
         12. Willing and able to return for the follow-up (FU) visits&#xD;
&#xD;
         13. Able to read and understand study instructions, and willing and able to comply with&#xD;
             all study procedures&#xD;
&#xD;
         14. Adequately informed of the nature and risks of the study and give written informed&#xD;
             consent before receiving any study specific assessments or procedures&#xD;
&#xD;
         15. Stable use of non-prescription pain therapy, including massage, TENS, physiotherapy&#xD;
             osteopathy, chiropractic and acupuncture for 2 months prior and throughout the study&#xD;
             period&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Subjects must NOT meet any of the following exclusion criteria:&#xD;
&#xD;
          1. Hypersensitivity, allergy, or significant reaction to any ingredient of the study drug&#xD;
&#xD;
          2. Any spinal deformity preventing intrathecal injection or making intrathecal injection&#xD;
             unsafe&#xD;
&#xD;
          3. Prior history of lumbar surgery, including fusion and microdiscectomy&#xD;
&#xD;
          4. History of epidural block or facet block or steroid injection in the last 6 months&#xD;
&#xD;
          5. Current unstable angina, uncontrolled congestive heart failure, or &gt;1+ pitting edema&#xD;
             of lower extremities&#xD;
&#xD;
          6. History of acute myocardial infarction, transient ischemic attack, stroke, or seizure&#xD;
             within 3 months of screening visit&#xD;
&#xD;
          7. Severe chronic obstructive or restrictive pulmonary disease&#xD;
&#xD;
          8. Current insulin dependent diabetes mellitus&#xD;
&#xD;
          9. Current autoimmune conditions or documented immunodeficiency&#xD;
&#xD;
         10. History of immunosuppressive therapy; high-potency systemic steroids in the last 3&#xD;
             months&#xD;
&#xD;
         11. Current treatment with systemic immunosuppressive (systemic corticosteroid therapy&#xD;
             [equivalent to &gt;10mg/day prednisone] or other strong immunosuppressant)&#xD;
&#xD;
         12. Current or history of central nervous system cancer&#xD;
&#xD;
         13. Any malignancy (EXCEPTION: localized non-melanoma skin cancers) within 5 years before&#xD;
             the screening visit or currently receiving systemic chemotherapy, radiation therapy,&#xD;
             or a surgical stabilization procedure&#xD;
&#xD;
         14. Significant hepatic disease as indicated by clinical laboratory results for the&#xD;
             following: ≥3 times the upper limit of normal (ULN) for aspartate aminotransferase,&#xD;
             alanine aminotransferase, ≥ 2.5 time ULN alkaline phosphatase, or ≥1.5 times ULN for&#xD;
             total bilirubin)&#xD;
&#xD;
         15. Severe anemia (Grade 3; hemoglobin &lt;8.0 g/dL, &lt;4.9 mmol/L, &lt;80 g/L; transfusion&#xD;
             indicated), Grade 1 white cell counts (lymphocytes &lt;LLN - 800/mm3; &lt;LLN - 0.8 x 109&#xD;
             /L, neutrophils &lt;LLN - 1500/mm3; &lt;LLN - 1.5 x 109 /L)&#xD;
&#xD;
         16. Significant renal disease as indicated by creatinine ≥1.5 times the upper limit of&#xD;
             normal or creatinine clearance &lt;80 mL/minute (Cockcroft-Gault formula estimate)&#xD;
&#xD;
         17. Confirmed positive for human immunodeficiency virus, hepatitis B virus, or hepatitis C&#xD;
             virus&#xD;
&#xD;
         18. Significant psychological conditions; dementia, major depression, or altered mental&#xD;
             state that in the opinion of the Investigator will interfere with study participation&#xD;
&#xD;
         19. Current treatment with systemic antibiotics or antivirals (EXCEPTION: topical&#xD;
             treatments)&#xD;
&#xD;
         20. Current treatment with anticoagulant or antiplatelet medications (EXCEPTION: aspirin&#xD;
             and other NSAIDs)&#xD;
&#xD;
         21. Current use of systemic corticosteroids (equivalent to &gt;10mg/day prednisone)&#xD;
&#xD;
         22. Known or suspected history of active alcohol or illicit drug abuse within 1 year&#xD;
             before the screening visit&#xD;
&#xD;
         23. Women who are pregnant or nursing&#xD;
&#xD;
         24. Use of any investigational drug or device within 1 month before randomization or&#xD;
             current participation in a trial that included intervention with a drug or device; or&#xD;
             currently participating in an investigational drug or device study&#xD;
&#xD;
         25. Any condition that, in the opinion of the Principal Investigator, could compromise the&#xD;
             safety of the subject, the subject's ability to communicate the study staff, or the&#xD;
             quality of the data&#xD;
&#xD;
         26. Presence of an implanted intrathecal infusion system or peripheral neurostimulator&#xD;
&#xD;
         27. Presence of a generalized pain disorder such as fibromyalgia or complex regional pain&#xD;
             syndrome that in the opinion of the PI may impact on evaluation of response to the&#xD;
             study drug&#xD;
&#xD;
         28. Diagnosis of peripheral neuropathy of the lower extremities which in the opinion of&#xD;
             the PI, might interfere with the subject's ability to assess the effect of the study&#xD;
             drug on the radicular signs and/or symptoms&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stephen Collins, MD/PhD</last_name>
    <role>Study Director</role>
    <affiliation>Xalud Therapeutics, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Elspeth Hutton, MBBS,PhD,FRACP</last_name>
    <phone>+61 3 9903 0781‬</phone>
    <email>elspeth.hutton@monash.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Mahima Kapoor</last_name>
    <email>M.Kapoor@alfred.org.au</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Genesis Research Services</name>
      <address>
        <city>Newcastle</city>
        <state>New South Wales</state>
        <zip>2292</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Marc Russo, MD</last_name>
      <phone>+61 2 4985 1860</phone>
      <email>reception@genesisresearchservices.com</email>
    </contact>
    <investigator>
      <last_name>Marc Russo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Alfred Health</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3004</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jack Germaine</last_name>
      <phone>+61 3 9076 2029</phone>
      <email>j.germaine@alfred.org.au</email>
    </contact>
    <investigator>
      <last_name>Elspeth Hutton, MBBS PhD FRACP</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mahima Kapoor</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>June 24, 2020</study_first_submitted>
  <study_first_submitted_qc>July 9, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">July 10, 2020</study_first_posted>
  <last_update_submitted>October 22, 2021</last_update_submitted>
  <last_update_submitted_qc>October 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 25, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>XT-150</keyword>
  <keyword>Plasmid Gene Therapy</keyword>
  <keyword>IL-10</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neuralgia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

